Remove Protein Expression Remove Protein Production Remove Vaccine
article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

For instance, the engineering of CHO cells, widely used protein expression system, for various metabolic pathways has resulted in improved expression levels of large molecule drugs and product quality 1,2. After engineering, stable clones are screened, identified, and characterised. Biotechnol Bioeng 2012;118:2326.

article thumbnail

JS Bio and Etta Biotech Advancing Strategic Partnership

The Pharma Data

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

As discussed above, recent advances in gene editing tools and transposon-based vectors have facilitated targeted and consistent cell line engineering for the development of protein expressing CHO cell lines. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News at Mary Ann Liebert, Inc.

article thumbnail

The future outlook for mRNA therapies

Drug Discovery World

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. mRNA is a molecule made up of a single strand of ribonucleic acid (RNA).

Therapies 130
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

The presentations include: Mark Cragg, PhD, Professor of Experimental Cancer Biology, Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, on: ‘Modulating antibody effector functions in the tumour microenvironment’. CCO & Co-Founder, ATUM, on: “Using machine learning to predict protein expression”.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It From a product perspective, RedShiftBio had the Aurora protein analyser with them in Lisbon this year.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Next-generation immunotherapies The fourth track of PEGS Europe 2023 on the third day is ‘Next-generation immunotherapies’, which will feature a range of sessions made up of presentations, talks and posters which address cell-based immunotherapies, vaccines, and checkpoints and agonists.